

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Topic selection and scoping

MT568 Magtrace and Sentimag for locating sentinel lymph nodes for breast cancer

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

1. Have any potential equality issues been identified during the development of the topic briefing note or during selection, and, if so, what are they?

People with breast cancer are protected under the Equalities Act 2010. The intended population includes people with invasive breast cancer and people with high-grade ductal carcinoma in-situ breast cancer.

The contraindications of Magtrace include people with known hypersensitivity to iron oxide or dextran compounds, people with iron overload disease and people with a metal implant in the axilla or in the chest. These groups of people may be excluded from treatment with the technology.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The committee should consider the impact that the known contraindications may have on access to Magtrace and Sentimag for people with protected characteristics.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No. The information above has been included as a special consideration.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues were identified during the scoping process.

Approved by Associate Director: Anastasia Chalkidou

Date: 14/12/2021